Abstracting & Coding Boot Camp: Cancer Case Scenarios

2015-2016 NAACCR Webinar Series

Q&A

• Please submit all questions concerning webinar content through the Q&A panel.
• Reminder:
  • If you have participants watching this webinar at your site, please collect their names and emails.
    • We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.
Fabulous prizes

Agenda

- Updates
- Anatomy and Medical Terminology
- Data Items/Epi Moment
- Staging
- Break
- Treatment
- Review of Take Home Quizzes
2016 & 2017 Updates

Stage Data Items

- For cases diagnosed 2015 and earlier all CS data items are required
- Data items going away for cases diagnosed 2016 and after.
  - CS Ext
  - CS Tumor Size
  - CS Tumor Size/Ext Eval
  - CS Lymph Nodes
  - CS Lymph Nodes Eval
  - CS Mets at DX
  - CS Mets Eval
  - CS Mets at Dx-Bone, Brain, Liver, Lung
New Stage Data Items

- Tumor Size Summary (NPCR and CoC)
- Tumor Size Clinical (SEER only)
- Tumor Size Pathologic (SEER only)
- Mets at Diagnosis - Distant Lymph Nodes
- Mets at Diagnosis – Bone
- Mets at Diagnosis – Brain
- Mets at Diagnosis – Liver
- Mets at Diagnosis – Lung
- Mets at Diagnosis – Other

Stage Data Items

- Data items we will continue to collect for cases diagnosed 2016 and forward.
  - Regional Nodes Positive and Regional Nodes Examined
  - CS Input Original and CS Input Current
    - These items are generated by your computer
  - CS Site Specific Factors (SSF)
    - For 2016 CoC requires the same SSF’s as in 2015
    - For 2016 SEER and NPCR have dropped some of their requirements
  - Lymph Vascular Invasion
    - For Penis and Testis schemas
TNM Classification Designator (c&p)

- Beginning with cases abstracted using the v16 layout, a “c” or “p” classification designator will be added to all T, N, and M values.
  - The designators indicate how the values entered into the T, N, and M data items were assigned.
  - This will make it easier to show when a clinical value is used to determine a pathologic stage or when a pathologic value is used to determine a clinical stage.

- All cases diagnosed after 1/1/2016 will need to have a classification designator included in the T, N, or M values.
- CoC will require their reporting facilities to add the classification designators to the T, N, and M values to historical cases on their registry. They will also require that all cases abstracted after the v16 update include the classification indicators regardless of diagnosis year.
- State and regional registries will have to determine if they want cases diagnosed prior to 2016 to include the classification designators.
  - In the central registry database
  - Incoming records
Updates

- AJCC 8th Edition
  - Scheduled for release mid 2016
  - Effective for cases diagnosed 2017 and forward
- FORDS 2016
- Cancer Program Standards 2016
  - [https://www.facs.org/quality-programs/cancer/coc/standards](https://www.facs.org/quality-programs/cancer/coc/standards)

Updates

- Summary Stage 2017
- ICD O 3 Implementation
- Solid Tumor Coding Manual and Solid Tumor Database
  - Will replace the MP/H Manual
- Hematopoietic Database
- SEER Rx
  - The web-based version is updated in real time.
  - Stand alone version requires periodic updates (auto updates).
- NAACCR Vol II Appendix G- Recommended Abbreviations for Abstractors
Revision of TNM Staged By Data Items

- The length of the TNM Path Staged By and TNM Clin Staged By data items has been expanded to 2 digits to accommodate new codes.
- The historic 1 character codes will be converted to the new codes upon upgrade to NAACCR v16-compliant software.

Questions?
Anatomy and Medical Terminology

Quiz 1

Questions?
Data Items: Outcomes

- Date of First Recurrence
  - Measure the effectiveness of first course treatment
- Type of First Recurrence
  - Used to evaluate treatment effectiveness and as a long-term prognostic factor
Date Items: Outcomes

- Date of Last Contact
  - Used for patient follow-up and outcomes studies
- Vital Status
  - Verifies the vital status of patient as of the date entered in Date of last Contact
- Cancer Status
  - Records if there is clinical evidence of the patients cancer as of the Date of Last Contact


And now a brief pause for...

An Epi Moment

(theme song of the moment…”I Will Survive”)
Follow-up variables commonly used in research

- Vital Status
- Cause of death
- Date last contact
- Treatment
- Treatment dates
- Cancer status
  - NCDB only
- Recurrence
  - NCDB only

Survival Analysis

- Survival analysis is used to assess the success of cancer treatment programs and cancer control programs
- Required variables: vital status (or some other outcome like recurrence) and date of last follow-up (if not deceased or no recurrence) and cause of death
- **Survival rate**: summary variable-% of people alive after a given period of time
  - Observed, expected, relative, cause-specific
- Survival curve
- Censoring
Coming soon……

- Inclusion criteria
  - Consent
  - CINA high quality data
  - SEER standard for follow-up
    - 90% of patients have current follow-up dates (or deceased)
    - 2005-2011-
      - follow-up dates Jan 1, 2012+
  - OR state & national death linkages
- 8 of 13 Canadian Provinces
  - 63% national coverage
  - 1 no consent; 1 data quality not met
    - 3 did not meet follow-up criteria
- 28 of 51 US states+ DC
  - 62% of US
  - 2 no consent; 3 data quality not met
    - 18 did not meet follow-up criteria

Outcomes research

- What treatment is effective?
  - Survival, interventions (screening and early diagnosis)
- Are standards of care followed?
- Comparative effectiveness research (CER)
- Impact of treatment delay
- Disparities in care
  - SES, insurance status or type, distance to care, regional or hospital differences,
Recent publications


Questions?
Staging

Quiz 2

Break
Treatment

Quiz 3

Questions?
Take Home Quizzes

MP/H
Staging

Questions?
Coming Up…

- Collecting Cancer Data: Ovary
  - 4/7/16
- Collecting Cancer Data: Kidney
  - 5/5/16

Fabulous prizes
CE Certificate Quiz/Survey

- Phrase
  - Outcomes
- Link

Thank You!

Jim Hofferkamp, CTR  jhofferkamp@naaccr.org
Angela Martin, CTR  amartin@naaccr.org
Recinda Sherman, PhD, CTR  rsherman@naaccr.org